UMB Bank n.a. Buys 32 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

UMB Bank n.a. increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 41.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 109 shares of the medical research company’s stock after purchasing an additional 32 shares during the period. UMB Bank n.a.’s holdings in Bio-Rad Laboratories were worth $36,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Van ECK Associates Corp boosted its position in shares of Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after purchasing an additional 644,530 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Bio-Rad Laboratories during the third quarter valued at approximately $83,681,000. Wedge Capital Management L L P NC bought a new position in Bio-Rad Laboratories in the 4th quarter worth $28,740,000. Mawer Investment Management Ltd. grew its holdings in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Bio-Rad Laboratories by 38.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,782 shares of the medical research company’s stock valued at $29,036,000 after buying an additional 24,052 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Up 1.1 %

Shares of NYSE BIO opened at $356.25 on Friday. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99. The company has a market capitalization of $9.98 billion, a price-to-earnings ratio of -13.04 and a beta of 0.90. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The business has a 50-day moving average of $336.56 and a two-hundred day moving average of $333.06.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.33 earnings per share. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIO has been the subject of a number of research reports. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.